To the Editor: Linezolid is the first oxazolidinone antibiotic with labeling approved to treat methicillin-resistant Staphylococcus aureus (MRSA) infection. We report 3 cases of myelosuppression with red cell hypoplasia that occurred following therapy with linezolid. Although reversible thrombocytopenia has been reported in patients receiving more than 2 weeks of therapy,1 we found additional bone marrow changes that appear similar to those seen in reversible chloramphenicol toxicity.